These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Determinants of European parents' decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. Tabacchi G; Costantino C; Napoli G; Marchese V; Cracchiolo M; Casuccio A; Vitale F; Hum Vaccin Immunother; 2016 Jul; 12(7):1909-23. PubMed ID: 27163657 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Pebody RG; Gay NJ; Hesketh LM; Vyse A; Morgan-Capner P; Brown DW; Litton P; Miller E Vaccine; 2002 Jan; 20(7-8):1134-40. PubMed ID: 11803074 [TBL] [Abstract][Full Text] [Related]
25. Vaccination Against Measles, Mumps, and Rubella in the Light of Current Epidemic Threats: Unjustified Postponement. Czajka H; Czajka S; Dyląg KA; Borek E; Kuchar E Adv Exp Med Biol; 2019; 1153():101-107. PubMed ID: 30758772 [TBL] [Abstract][Full Text] [Related]
26. Measles, mumps and rubella: control by vaccination. van Druten JA; de Boo T; Plantinga AD Dev Biol Stand; 1986; 65():53-63. PubMed ID: 3556777 [TBL] [Abstract][Full Text] [Related]
27. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine]. He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345 [TBL] [Abstract][Full Text] [Related]
28. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Prymula R; Bergsaker MR; Esposito S; Gothefors L; Man S; Snegova N; Štefkovičova M; Usonis V; Wysocki J; Douha M; Vassilev V; Nicholson O; Innis BL; Willems P Lancet; 2014 Apr; 383(9925):1313-1324. PubMed ID: 24485548 [TBL] [Abstract][Full Text] [Related]
29. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Carryn S; Feyssaguet M; Povey M; Di Paolo E Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639 [TBL] [Abstract][Full Text] [Related]
30. Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 Months During a Measles Outbreak in The Netherlands in 2013-2014. van der Maas NA; Woudenberg T; Hahné SJ; de Melker HE J Infect Dis; 2016 May; 213(9):1466-71. PubMed ID: 26690343 [TBL] [Abstract][Full Text] [Related]
31. Why do parents hesitate to vaccinate their children against measles, mumps and rubella? Alfredsson R; Svensson E; Trollfors B; Borres MP Acta Paediatr; 2004 Sep; 93(9):1232-7. PubMed ID: 15384890 [TBL] [Abstract][Full Text] [Related]
32. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. Sørup S; Benn CS; Poulsen A; Krause TG; Aaby P; Ravn H JAMA; 2014 Feb; 311(8):826-35. PubMed ID: 24570246 [TBL] [Abstract][Full Text] [Related]
33. Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s. Geier DA; Kern JK; Geier MR BMC Pediatr; 2019 Sep; 19(1):325. PubMed ID: 31506095 [TBL] [Abstract][Full Text] [Related]
34. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996]. Zäch K; Nicoara C; Germann D; Matter L Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837 [TBL] [Abstract][Full Text] [Related]
35. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study. Bae GR; Choe YJ; Go UY; Kim YI; Lee JK Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654 [TBL] [Abstract][Full Text] [Related]
36. [Evaluation of 44 pediatric measles cases detected in Ankara, Turkey during 2012-2013 epidemic and molecular characterization of the viruses obtained from two cases]. Metin O; Tanir G; Oz FN; Kalaycioglu AT; Yolbakan S; Tuygun N; Bayhan GI; Aydin Teke T; Korukluoglu G Mikrobiyol Bul; 2014 Apr; 48(2):259-70. PubMed ID: 24819263 [TBL] [Abstract][Full Text] [Related]
37. MMR vaccination and disease elimination: the Finnish experience. Davidkin I; Kontio M; Paunio M; Peltola H Expert Rev Vaccines; 2010 Sep; 9(9):1045-53. PubMed ID: 20822347 [TBL] [Abstract][Full Text] [Related]
38. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella. Wellington K; Goa KL Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524 [TBL] [Abstract][Full Text] [Related]
39. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Christenson B; Böttiger M Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016 [TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years. Vesikari T; Baer M; Willems P Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]